Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $10.1 million.

  • Cumberland Pharmaceuticals' Other Accumulated Expenses fell 2034.25% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 2034.25%. This contributed to the annual value of $12.3 million for FY2024, which is 989.64% down from last year.
  • Cumberland Pharmaceuticals' Other Accumulated Expenses amounted to $10.1 million in Q3 2025, which was down 2034.25% from $10.1 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Other Accumulated Expenses registered a high of $17.6 million during Q4 2022, and its lowest value of $7.6 million during Q3 2021.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $12.3 million (2022), whereas its average is $12.3 million.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Other Accumulated Expenses plummeted by 2466.54% in 2021 and then skyrocketed by 10289.91% in 2022.
  • Over the past 5 years, Cumberland Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $8.7 million in 2021, then skyrocketed by 102.9% to $17.6 million in 2022, then decreased by 22.69% to $13.6 million in 2023, then fell by 9.9% to $12.3 million in 2024, then fell by 17.75% to $10.1 million in 2025.
  • Its Other Accumulated Expenses was $10.1 million in Q3 2025, compared to $10.1 million in Q2 2025 and $11.2 million in Q1 2025.